PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly

O’Toole, Dermot; Kunz, Pamela L.; Webb, Susan M.; Goldstein, Grace; Khawaja, Sheila; Boiziau, Sandra; Houchard, Aude; Ribeiro‐Oliveira, Antônio; Prebtani, Ally

doi:10.1007/s12325-022-02360-6

Cited by 12 publications

(4 citation statements)

References 19 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The safety profile is not different between OCT and LAN. However, from a practical point of view, LAN was reported to be easier to manage than OCT and less frequently complicated by pain and technical problems, because of the autogel formulation with a comfortable device and a fast administration [ 31 , 32 ].…”

Section: Resultsmentioning

confidence: 99%

Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story

Faggiano

2023

J Endocrinol Invest

View full text Add to dashboard Cite

Purpose The specific indications of somatostatin analogs (SSAs) in patients with neuroendocrine tumor (NET) emerged over the time. The objective of this review is to summarize and discuss the most relevant data concerning long-acting SSAs in NET. Methods A narrative review was performed including publications focusing on therapy with the long-acting octreotide, lanreotide, and pasireotide in patients with NET. Results Long-acting SSAs confirm to be a manageable and widely used tool in patients with NET. Both long-acting octreotide and lanreotide are safe as the short-acting formulations, while patient compliance and adherence is further improved. Together with some randomized phase-3 trials, many retrospective and prospective studies have been performed in the last 20 years revealing a variable but substantial impact on progression free survival, not only in gastroenteropancreatic but also in lung and unknown primary NETs. The most frequent tumor response to SSAs is stable disease, but an objective response can be observed, more frequently by using high-dose schedules and in MEN1-related pancreatic NETs. Low tumor burden, low tumor grade (G1 and low G2), good performance status and use as first-line therapy are the main predictive factors to SSAs in NET patients. Pasireotide has been evaluated in few studies. This compound remains a promising SSA and would deserve to be further evaluated as a potential additional indication in NET therapy. Conclusions Long-acting SSAs are an effective and safe initial therapy of patients with well differentiated NET, allowing tumor growth as well as symptoms control for long-time in selected patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story

Faggiano

2023

J Endocrinol Invest

View full text Add to dashboard Cite

show abstract

“…Some participants indicated that their choice of HCP administration was influenced by the fear (14.1%) or the anxiety (11.1%) that could occur with independent injection, though out of all participants, only three reported that they felt "Very anxious" or "Extremely NETs or acromegaly treated with LAN or OCT, some degree of preinjection anxiety was reported by approximately half of the survey participants (LAN, 59.5%; OCT, 43.7%). 12 It is possible that enhanced training and support could increase patients' confidence in their own or their caregiver's injection abilities and, at least in part, help to mitigate preinjection anxiety and resistance to independent injections.…”

Section: Discussionmentioning

confidence: 99%

“…Of 119 patients who completed the questionnaire, only 2% of the 51 patients receiving LAN who answered the question, reported moderate to high anxiety prior to injection (vs. 11% of 66 patients treated with OCT) 11 . In the recent PRESTO 2 survey ( n = 304), which assessed the injection experience of patients with NETs or acromegaly treated with LAN or OCT, some degree of preinjection anxiety was reported by approximately half of the survey participants (LAN, 59.5%; OCT, 43.7%) 12 . It is possible that enhanced training and support could increase patients' confidence in their own or their caregiver's injection abilities and, at least in part, help to mitigate preinjection anxiety and resistance to independent injections.…”

Section: Discussionmentioning

confidence: 99%

Satisfaction with injection experience of patients with neuroendocrine tumors enrolled on lanreotide autogel patient support programs: Results from the international HomeLAN survey

Hernando¹,

Kolarova²,

Verslype

et al. 2023

J Neuroendocrinology

Self Cite

View full text Add to dashboard Cite

Lanreotide autogel/depot (LAN) is a somatostatin analog used in first‐line treatment for neuroendocrine tumors (NETs). The aim of HomeLAN was to evaluate the satisfaction with injection experience among patients with NETs receiving at‐home LAN injection via patient support programs (PSPs). This was an international, non‐interventional, cross‐sectional, online survey in adults with NETs enrolled in PSPs, receiving LAN injections at home, administered by a healthcare professional (HCP) or administered independently (self or caregiver administering injection). The primary endpoint was satisfaction with the most recent LAN injection. Secondary endpoints included the level of anxiety prior to injection, impact on daily life, and the extents to which participants felt in control of their life and agreed that home administration met their medical needs. In total, 111 participants from Belgium, Greece, the Netherlands, and Spain completed the survey (50.5% male; mean age, 63.6 years; most common primary tumor site was intestine [47.7%]). For 99 participants, their most recent injection was administered by an HCP. Overall, 95.5% of all participants were satisfied with their most recent injection experience (95% confidence interval: 89.89%–98.06%); 67% reported experiencing no anxiety prior to injection, 91.0% reported that home injection had a “great deal” or “quite a bit” of positive impact on their daily life, and 85.6% strongly agreed that the PSP met their medical needs. In the HCP injection subgroup, 71.7% reported that this mode of administration helped them to feel in control of their lives. In this patient survey, satisfaction levels were high among patients with NETs receiving LAN injections at home via a LAN PSP. Most patients did not experience anxiety prior to their most recent injection and acknowledged that thanks to their treatment they had a good quality of life despite their disease. Most strongly agreed that the PSP met their medical needs, which highlights the valuable service that LAN PSPs provide for patients with NETs.

show abstract

“…Patients' preference for at-home administration may be, in part, supported by having LAN as a ready-to-use pre-filled syringe. Indeed, patients have previously reported that they were less likely to experience prolonged pain or technical issues with this device than with the latest octreotide long-acting release formulation (Novartis) [12]. Additionally, in an international simulated-use study, nurses administering lanreotide strongly preferred the user experience of the LAN syringe used in this study (Somatuline Autogel) versus an alternative, the Lanreotide Pharmathen syringe [13].…”

Section: Discussionmentioning

confidence: 99%

PREF-NET: a patient preference and experience study of lanreotide autogel administered in the home versus hospital setting among patients with gastroenteropancreatic neuroendocrine tumours in the UK

Khan¹,

Davies²,

Back³

et al. 2022

EJEA

View full text Add to dashboard Cite

Purpose PREF-NET reported patients' experience of Somatuline® (lanreotide) Autogel® (LAN) administration at home and in hospital among patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Methods PREF-NET was a multicentre, cross-sectional study of UK adults (aged ≥ 18 years) with GEP-NETs receiving a stable dose of LAN, which comprised of (1) a quantitative online survey, and (2) qualitative semi-structured interviews conducted with a subgroup of survey respondents. The primary objective was the description of overall patient preference for home versus hospital administration of LAN. Secondary objectives included describing patient-reported opinions on the experience and associated preference for each administration setting, and the impact on healthcare utilisation, societal cost, activities of daily living and health-related quality of life (HRQoL). ResultsIn the primary analysis (80 patients; mean age 63.9 years), 98.7% (95% confidence interval [CI]: 96.1-100.0) of patients preferred to receive LAN at home, compared with 1.3% (95% CI: 0.0-3.9) who preferred the hospital setting. Among participants, over half (60.3%) received their injection from a non-healthcare professional. Most patients (79.5% [95% CI: 70.5-88.4]) reported a positive effect on HRQoL after the switch from hospital to home administration. Qualitative interviews (20 patients; mean age 63.6 years) highlighted that patients preferred home administration because it improved overall convenience; saved time and costs; made them feel more comfortable and relaxed, and less stressed; and increased confidence in their ability to self-manage their treatment. Conclusion Almost all patients preferred to receive LAN treatment at home rather than in hospital with increased convenience and psychological benefits reported as key reasons for this preference.

show abstract

PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly

Cited by 12 publications

References 19 publications

Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story

Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story

Satisfaction with injection experience of patients with neuroendocrine tumors enrolled on lanreotide autogel patient support programs: Results from the international HomeLAN survey

PREF-NET: a patient preference and experience study of lanreotide autogel administered in the home versus hospital setting among patients with gastroenteropancreatic neuroendocrine tumours in the UK

Contact Info

Product

Resources

About